Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Schwitzguebel A, Ramirez Cadavid DA, Benaim C, Da Silva T, Decavel P
Effectiveness of Stromal Vascular Fraction (SVF) and Platelet-Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Protocol for a Phase 3, Prospective, Randomized, Controlled, Multicenter Study (SPOST Study)
Effectiveness of Stromal Vascular Fraction (SVF) and Platelets Rich Plasma (PRP) in patients with knee Osteoarthritis: Study protocol for a phase III, prospective, randomized, controlled multi-center study: (SPOST study)
Adrien Schwitzguebel;
David Andres Ramirez Cadavid;
Charles Benaim;
Tamara Da Silva;
Pierre Decavel
ABSTRACT
Background:
Available evidence on the conservative treatment of osteoarthritis still leaves the place for questioning on the efficacy of Platelet-Rich Plasma (PRP) and on whether Stromal Vascular Fraction (SVF) offers a superior therapeutic tool.
Objective:
To assess the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration for osteoarthritis.
Methods:
In a multi-centric, randomized, triple-blind controlled trial, 130 individuals with osteoarthritis will be block-randomized in a 1:1 ratio. Patients will receive an initial single PRP or PRP + SVF injection, followed by one- and two-months PRP doses. The primary endpoint is the functional improvement measured with the Single Assessment Numeric Evaluation (SANE) scale at 6 months follow-up. The secondary endpoints, gathered at 3, 6, and 12 months follow-up will include clinical outcomes: Low Extremity Functional Scale (LEFS) and Quick Disabilities of the Arm, Shoulder and Hand (quick-DASH) score, Pain Visual Analogue Scale (VAS) during maximal physical activity, SANE, the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) (in knee osteoarthritis cases), return to work and to sports in days; and Magnetic Resonance Imaging (MRI) AMADEUS score at 6 months and at 12 months.
Results:
Participants recruitment and data collection is expected to begin in August 2024. Final end-points will be gathered in august 2027.
Conclusions:
The study results will provide insight into the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration in osteoarthritis. This trial is registered on ClinicalTrials.gov (NCT05660824) and SNCTP Clinical Trial: This trial is registered on ClinicalTrials.gov (NCT05660824) and SNCTP.
Citation
Please cite as:
Schwitzguebel A, Ramirez Cadavid DA, Benaim C, Da Silva T, Decavel P
Effectiveness of Stromal Vascular Fraction (SVF) and Platelet-Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Protocol for a Phase 3, Prospective, Randomized, Controlled, Multicenter Study (SPOST Study)